MAIA Biotechnology Completes Global Enrollment for Phase 2 Ateganosine Trial in Refractory NSCLC

June 28, 2026

GlobeNewswire USA

Overview

MAIA Biotechnology has completed global enrollment for Part C of its Phase 2 THIO-101 expanded trial, evaluating ateganosine for third-line advanced non-small cell lung cancer (NSCLC). Ateganosine, an investigational drug with a dual mechanism targeting telomeres and immune activation, holds FDA Fast Track designation for NSCLC. This crucial milestone significantly accelerates the development of a potential new treatment for a patient population with high unmet medical needs.

In Depth

Background

Non-small cell lung cancer (NSCLC) stands as one of the most prevalent cancers globally, often carrying a poor prognosis in its advanced stages. For patients requiring third-line treatment, particularly those who have become resistant to prior first- and second-line therapies, effective and safe treatment options remain critically limited. MAIA Biotechnology actively addresses this unmet medical need through the development of ateganosine (THIO-101), an investigational drug with a novel dual mechanism of action.

Ateganosine is designed to induce telomere dysfunction while simultaneously activating the immune system. Cancer cells commonly overexpress telomerase to circumvent the natural shortening of telomeres, which typically limits cell division. By targeting this telomere regulatory mechanism, ateganosine aims to trigger apoptosis (programmed cell death) in cancer cells. Furthermore, it is believed to enhance the anti-tumor immune response within the tumor microenvironment. The U.S. Food and Drug Administration (FDA) has recognized the potential importance of ateganosine by granting it Fast Track designation for NSCLC, a program intended to expedite the development of treatments for serious conditions.

Key Findings

MAIA Biotechnology has announced the successful completion of international enrollment for Part C of its Phase 2 THIO-101 expanded clinical trial. This trial evaluates ateganosine as a potential third-line therapeutic option for patients with advanced non-small cell lung cancer. This pivotal milestone signifies a substantial advancement in bringing new treatment modalities to patients grappling with advanced cancers, especially those with severely restricted treatment alternatives. The FDA’s earlier Fast Track designation for ateganosine in NSCLC further underscores the urgency and potential impact of this therapeutic candidate.

Significance & Outlook

The completion of global enrollment for the Phase 2 trial Part C marks a critical juncture in ateganosine’s clinical development, paving the way for accelerated data collection and analysis. Should this trial yield promising efficacy and safety data, it will significantly advance the drug toward further late-stage clinical development and potential expedited regulatory approval. A successful outcome for ateganosine would introduce a powerful new treatment option for third-line advanced NSCLC, offering a ray of hope for improving patient prognoses and quality of life.

For MAIA Biotechnology, this achievement represents a major enhancement in its pipeline value and validates its strategic focus on innovative cancer therapies. The company anticipates that ateganosine will play a crucial role in addressing the substantial unmet medical need within the advanced NSCLC patient population, potentially transforming treatment paradigms.

Source: https://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/maia-biotechnology-completes-international-enrollment-in-part-c-of-phase-2-thio-101-expansion-trial-in-third-line-non-small-cell-lung-cancer.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.